Get the Stockscreener App
4.35
2.84%
0.12
After Hours:
4.38
0.03
+0.69%
Black Diamond Therapeutics Inc stock is traded at $4.35, with a volume of 1.38M.
It is up +2.84% in the last 24 hours and down -28.69% over the past month.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$4.23
Open:
$4.2
24h Volume:
1.38M
Relative Volume:
1.19
Market Cap:
$237.60M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.9079
EPS:
-2.28
Net Cash Flow:
$-66.75M
1W Performance:
-3.33%
1M Performance:
-28.69%
6M Performance:
-14.20%
1Y Performance:
+51.57%
1-Day Range:
$4.175
$4.43
1-Week Range:
$3.93
$4.90
52-Week Range:
$1.62
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Stock Surge: Black Diamond Therapeutics Inc (BDTX) Closes at 4.23, Marking a -4.08 Increase/Decrease - The Dwinnex
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - US Post News
A company insider recently sold 221,600 shares of Black Diamond Therapeutics Inc [BDTX]. Should You Sale? - Knox Daily
A look into Black Diamond Therapeutics Inc (BDTX)’s deeper side - SETE News
Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
BlackGold Secures Critical Extension for Proposal - TipRanks
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Black Diamond Therapeutics (NASDAQ:BDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Black Diamond shares hold buy rating on Phase 2 results - Investing.com India
BlackLine ticks higher as board appointment stokes some takeover speculation - Seeking Alpha
Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Ally Bridge Group NY LLC Buys New Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso - openPR
TD Cowen maintains Buy on Black Diamond Therapeutics - Investing.com India
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $15.00 at Piper Sandler - MarketBeat
Black Diamond Therapeutics Target of Unusually High Options Trading (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics (NASDAQ:BDTX) PT Raised to $15.00 at Piper Sandler - Defense World
Black Diamond Therapeutics price target raised to $15 from $12 at Piper Sandler - TipRanks
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise - Fierce Biotech
Traders Buy High Volume of Put Options on Black Diamond Therapeutics (NASDAQ:BDTX) - MarketBeat
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug - Yahoo Finance
Can you still get a good price for Black Diamond Therapeutics Inc (BDTX) Shares at this point? - US Post News
Ally Bridge Group NY LLC Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Ally Bridge Group NY LLC Decreases Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Black Diamond reports encouraging Phase 2 data for BDTX-1535 (update) - Seeking Alpha
Black Diamond Therapeutics Inc’s Market Journey: Closing Weak at 4.76, Down -0.42 - The Dwinnex
Black Diamond Therapeutics Shares Jump on Positive Data for Cancer Treatment - MarketWatch
Black Diamond Therapeutics Reports Promising BDTX-1535 Results - TipRanks
Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire
Black Diamond announces initial Phase 2 data of BDTX-1535 - TipRanks
Black Diamond advances NSCLC treatment in Phase 2 trial - Investing.com
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations - Yahoo Finance
Renaissance Technologies LLC Acquires 8,700 Shares of Park Aerospace Corp. (NYSE:PKE) - Defense World
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - ForexTV.com
Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - StockTitan
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years - Benzinga
10% Owner Versant Venture Capital VI, L. sale 221,600 shares of Black Diamond Therapeutics Inc [BDTX] - Knox Daily
PowerSchool Holdings Inc [NYSE: PWSC] Sees Increase in Stock Value - Knox Daily
Stanley Black & Decker Inc [SWK] Records 200-Day SMA of $91.92 - Knox Daily
Highbridge Capital Management LLC Increases Stock Position in Olink Holding AB (publ) (NASDAQ:OLK) - Defense World
Marathon Trading Investment Management LLC Has $92,000 Stock Holdings in National CineMedia, Inc. (NASDAQ:NCMI) - Defense World
MQS Management LLC Reduces Stock Position in McDonald’s Co. (NYSE:MCD) - Defense World
Rhumbline Advisers Purchases 10,646 Shares of Pitney Bowes Inc. (NYSE:PBI) - Defense World
Meiji Yasuda Asset Management Co Ltd. Purchases 119 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - Defense World
The Southern Company (NYSE:SO) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World
An analyst sees good growth prospects for Black Diamond Therapeutics Inc (BDTX) - SETE News
Equities Analysts Set Expectations for Ascendis Pharma A/S’s Q3 2024 Earnings (NASDAQ:ASND) - Defense World
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):